Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.57 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.56 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.56 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6513151 | 0.94 | CES1 (0.52) | ACHEDNMT1DNMT3LDNMT3AMEN1 | |
| SCHEMBL1296639 | 0.88 | ACHE (0.64) | ACHEDNMT1DNMT3LDNMT3AMEN1 | |
| SCHEMBL3455773 | 0.85 | RPS6KA2 (0.65) | ACHEDNMT1DNMT3LDNMT3AMEN1 | |
| SCHEMBL4449242 | 0.80 | ACHE (0.48) | ACHEHPGDKMT2ASMN1; SMN2 | |
| SCHEMBL22181870 | 0.79 | SIRT1 (0.57) | MEN1ALDH1A1MAPTHPGDHTT | |
| SCHEMBL31180742 | 0.78 | MEN1 (0.62) | ACHEDNMT1DNMT3LDNMT3AMEN1 | |
| SCHEMBL6777483 | 0.78 | TDP1 (0.75) | ACHEMEN1KMT2A | |
| SCHEMBL8862728 | 0.78 | TDP1 (0.75) | ACHEMEN1KMT2A | |
| SCHEMBL2604742 | 0.78 | TDP1 (0.75) | ACHEMEN1KMT2A | |
| SCHEMBL8862878 | 0.78 | TDP1 (0.75) | ACHEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450348-B2 | Such as 3-[6-(4-Chloro-phenoxy)-hexylamino]-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione; cancer, tumors; reduced side effects | FORMA TM, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450348-B2 | Such as 3-[6-(4-Chloro-phenoxy)-hexylamino]-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione; cancer, tumors; reduced side effects | FORMA TM, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| EP-2096107-A1 | Derivatives of squaric acid with anti-proliferative activity | GPC Biotech AG (DE) | 2009-09-02 | — | — | EP | disclosed |
| EP-1674457-B1 | Derivatives of squaric acid with anti-proliferative activity | GPC BIOTECH AG (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-20080200523-A1 | Derivatives of squaric acid with anti-proliferative activity | Valo Health, LLC | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200523-A1 | Derivatives of squaric acid with anti-proliferative activity | SQLE, FDFT1, DLD | ACHE 4586/4885DNMT1 2275/4885DNMT3L 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.